Glenview Trust Co bought a new position in Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,484 shares of the medical technology company's stock, valued at approximately $1,412,000.
Other large investors also recently modified their holdings of the company. Varma Mutual Pension Insurance Co raised its position in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company's stock valued at $18,842,000 after buying an additional 5,100 shares during the last quarter. QRG Capital Management Inc. grew its position in Stryker by 7.4% during the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company's stock worth $21,281,000 after buying an additional 4,186 shares in the last quarter. Swedbank AB increased its stake in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock valued at $45,349,000 after acquiring an additional 7,934 shares during the period. Crossmark Global Holdings Inc. increased its stake in Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company's stock valued at $9,426,000 after acquiring an additional 6,367 shares during the period. Finally, Royal Bank of Canada raised its holdings in Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock valued at $1,075,552,000 after acquiring an additional 199,863 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.
Stryker Price Performance
Shares of SYK stock opened at $331.32 on Friday. The stock's fifty day simple moving average is $329.10 and its 200 day simple moving average is $331.47. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The firm has a market cap of $127.08 billion, a price-to-earnings ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the prior year, the company posted $3.13 earnings per share. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.
Wall Street Analyst Weigh In
SYK has been the topic of several recent research reports. UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price objective on the stock. Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday, August 13th. The Goldman Sachs Group reiterated a "neutral" rating and set a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. Citigroup reissued a "buy" rating on shares of Stryker in a report on Thursday, August 13th. Finally, Piper Sandler dropped their price objective on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.
Read Our Latest Stock Report on Stryker
Insider Buying and Selling at Stryker
In other news, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 300,000 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last ninety days. Corporate insiders own 4.60% of the company's stock.
Stryker Company Profile
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
